# Relmada Therapeutics, Inc. (RLMD)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/RLMD/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 0 | $ -19.05M | $ -15.07M | $ 0 | $ 218.73M |
| 2025 | $ 0 | $ -58.76M | $ -46.88M | $ 0 | $ 86.51M |
| 2024 | $ 0 | $ -84.06M | $ -54.40M | $ 0 | $ 35.52M |
| 2023 | $ 0 | $ -106.82M | $ -55.86M | $ 0 | $ 85.36M |
| 2022 | $ 0 | $ -175.43M | $ -115.96M | $ 0 | $ 140.44M |
| 2021 | $ 0 | $ -149.48M | $ -109.21M | $ 0 | $ 208.26M |
| 2020 | $ 0 | $ -75.74M | $ -35.43M | $ 0 | $ 105.58M |
| 2019 | $ 0 | $ -19.37M | $ -15.61M | $ 110.2K | $ 115.68M |
| 2018 | $ 0 | $ -22.53M | $ -11.52M | $ 114.7K | $ 1.43M |
| 2017 | $ 0 | $ -8.11M | $ -6.75M | $ 1.39M | $ 721.2K |
| 2016 | $ 0 | $ -10.80M | $ -13.98M | $ 110.0K | $ 4.67M |
| 2015 | $ 0 | $ 8.12M | $ -22.60M | $ 88.5K | $ 11.76M |
| 2014 | $ 964 | $ -73.78M | $ -10.35M | $ 38.1K | $ 4.59M |
| 2013 | $ 6.9K | $ -71.6K | $ -34.5K | $ 0 | $ -28.0K |
| 2012 | $ 14.6K | $ -29.8K | $ -5.5K | $ 0 | $ 11.4K |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 0.00 |
| Liabilities / Eq | 0.08 |
| Current Ratio | 18.26 |

## Other views

- [Metrics](https://sponda.capital/en/RLMD.md)
- [Charts](https://sponda.capital/en/RLMD/charts.md)
- [Compare](https://sponda.capital/en/RLMD/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-13.